- Clinical-stage biotech Salarius Pharmaceuticals, Inc. ( NASDAQ: SLRX ) shed ~27% at the open Tuesday after the company said that following a death of the study subject it will pause enrollment of new patients in the Phase 1/2 trial for lead asset seclidemstat in connective tissue cancer.
- The three-patient arms study is designed to evaluate seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas.
- The company said that the death of a metastatic FET-rearranged sarcoma patient due to an event classified as a suspected unexpected serious adverse reaction (SUSAR) led to its decision to pause enrollment.
- However, following a review by the independent Safety Review Committee for the clinical trial, SLRX said that with supporting medical advice, the patients can continue to receive seclidemstat in the trial.
- The company remain on track to release interim data from the sarcoma trial before the year end.
For further details see:
Salarius drops 27% after patient death in cancer trial for lead asset